Article
Author(s):
WellDyneRx created an innovative program that controls costs and improves outcomes for patients with diabetes, according to a session presented at APhA2018.
Conference attendees at the PharmTalk: Innovative Practices in Diabetes Care presentation on Friday, March 16, at the American Pharmacists Association’s Annual Meeting & Exposition (APhA2018) in Nashville, Tennessee, learned how one independent pharmacy benefit manager (PBM) created an innovative program to help patients.
In one segment of the presentation, called Applying High-Touch Specialty Pharmacy Principles to Managing Diabetes, PattyTaddei-Allen, PharmD, BCACP, BCGP, director of outcomes research at WellDyneRx in Lakeland, Florida, talked about how the PBM figured out a way to marry cost savings with improving outcomes.
In late 2016, WellDyneRx was strategizing, thinking about what patients with diabetes both needed and wanted. The PBM knew that “diabetes is the leading driver of the traditional drug cost spend,” higher than the amount spent on oncology, multiple sclerosis, and HIV, Taddei-Allen said. It also knew that “adherence continues to be less than optimal,” she said.
For more information, please visit PharmacyTimes.com.
FDA Approves Bimekizumab-Bkzx as Treatment for Hidradenitis Suppurativa